Corporate Presentation August 2016
Presentation

ASH 2015 Investor and Analyst Event
Presentation

ASH 2014 Investor and Analyst Event
Presentation

 

2015 Annual Report
Download here

 

Derivative Lawsuit Settlement Information
Download here

 
Webcast ImageWebcast
Geron Corporation at Piper Jaffray 28th Annual Healthcare Conference (Replay)
11/30/16 at 12:30 p.m. ET
Geron Corporation at Piper Jaffray 28th Annual Healthcare Conference
Wednesday, November 30, 2016 12:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
11/07/16Geron Announces November Investor Conference Presentation WebcastsPrinter Friendly Version
11/03/16Geron Announces Presentations at American Society of Hematology Annual MeetingPrinter Friendly Version
11/03/16Geron Corporation Reports Third Quarter 2016 Financial Results and Recent EventsPrinter Friendly Version
Upcoming EventsMore >>
DateTitle
12/03/16
through
12/06/16
Geron Conference Presentation at American Society of Hematology Annual Meeting
LocationSan Diego, CA
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$2.01
Change (%) Stock is Up 0.05 (2.55%)
Volume726,954
Data as of 12/02/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7700
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)